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Abstract
APJ, a G protein-coupled seven-transmembrane receptor, has been shown to serve as a co-receptor for the entry of human immuno-
deficiency virus type 1 (HIV-1), and it is dramatically expressed in central nervous system (CNS)-based cells. ALX40-4C was identified
as a small-molecule antagonist of the chemokine receptor CXCR4, which can specifically inhibit HIV-1 entry via this co-receptor. In this
study, we demonstrated that ALX40-4C inhibited both APJ- and CXCR4/APJ-mediated cell membrane fusion in a dose-dependent manner.
In competitive binding assays, 125I-Apelin13 was replaced by ALX40-4C with an IC50 of 2.9 M, as compared with an IC50 of 0.2 nM for
Apelin13. Furthermore, ALX40-4C could block ligand-induced APJ internalization and signaling. ALX40-4C, as an antagonist to APJ,
directly binds to and prevents use of APJ as a HIV-1 co-receptor. Thus, ALX-4C has potential utility for further elucidation of HIV-1
neuropathogenesis and therapy of HIV-1-induced encephalopathy.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Entry of human immunodeficiency virus type I (HIV-1)
into human cells requires binding of the virus envelope
protein (gp120) to CD4, followed by interactions with a
seven-transmembrane-spanning G protein-coupled receptor,
as its co-receptor. All primary HIV-1 strains use the che-
mokine receptor CCR5 (M-tropic) or CXCR4 (T-cell-line-
tropic), or both (dual-tropic), as co-receptors (Choe et al.,
1996; Deng et al., 1996; Doranz et al., 1996; Dragic et al.,
1996; Feng et al., 1996). Recent studies have also shown
that the APJ receptor is employed by T-tropic, M-tropic,
dual-tropic, and simian immunodeficiency viruses (SIVs) in
supporting env-mediated membrane fusion or viral entry in
vitro (Choe et al., 1998; Edinger et al., 1998; Puffer et al.,
2000; Singh et al., 1999; Zhang et al., 1998). The APJ
receptor was found to be used as a co-receptor by some
brain-derived HIV-1 strains (Albright et al., 1999; Shieh et
al., 1998). With the detection of expression of APJ in the
central nervous system (CNS), these observations suggest
that the APJ receptor might play an important role in HIV-1
infection and pathogenesis in the CNS (Zhou et al., 2003).
Of note, Apelins are natural peptidic ligands for APJ and
have been demonstrated to be expressed in the CNS (see
Zhou et al., 2003, for a review), as well as to induce
chemotaxis in certain cell types (Hosoya et al., 2000).
The discovery of HIV-1 co-receptors has provided new
targets for specific anti-HIV-1 therapy. Therapeutic drugs
for inhibition of HIV-1 envelope interactions with co-recep-
tors are now being developed. ALX40-4C (N--acetyl-
nona-D-arginine amide), a polypeptide of nine arginine res-
idues stabilized by terminal protection and inclusion of
D-amino acids, was initially designed as an inhibitor of
HIV-1 Tat-TAR binding (Sumner-Smith et al., 1995). Sub-
sequently, ALX40-4C was identified as an inhibitor that
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interferes with initial virus–target cell interactions, which
involve HIV-1 gp120 V3 determinants, most efficiently for
T cell line-adapted strains (O’Brien et al., 1996). Further
studies have demonstrated that ALX40-4C interacts with
the second extracellular loop of CXCR4 and inhibits infec-
tion exclusively by blocking direct virus–CXCR4 interac-
tions (Doranz et al., 1997, 2001).
In this study, we further identified ALX40-4C as an
antagonist of the APJ receptor. We demonstrate that
ALX40-4C can bind to APJ, competing with the natural
ligands Apelin-13 and Apelin-36, block HIV-1 gp120-asso-
ciated cell membrane fusion, and inhibit ligand-induced
APJ internalization and intracellular Ca2 mobilization.
Results
Activities of ALX40-4C in blocking HIV-1 gp120/
APJ-mediated cell membrane fusion
In initial exploratory experiments, we used a gene re-
porter fusion assay to evaluate the abilities of Apelin-13 and
Apelin-36 peptides in blocking APJ- and 89.6 gp120-medi-
ated cell membrane fusion, and used ALX40-4C as a neg-
ative control. Surprisingly, we found that ALX40-4C was
able to block cell membrane fusion in this system (not
illustrated). Therefore, we further examined the activity of
ALX40-4C in inhibition of APJ-mediated cell membrane
fusion in detail. As shown in Fig. 1, ALX40-4C was found
to block cell membrane fusion using the T-tropic III B
envelope in a dose-dependent manner, and the inhibitory
activity of ALX40-4C was significant, but somewhat lower
than with Apelin-36 (Table 1).
We then infected effector 293 cells with different recom-
binant vaccinia viruses with HIV-1 Env gp120s for fusion
assays to compare the fusion inhibitory activities of Apelin-
13, Apelin-36, and ALX40-4C. The results demonstrated
that Apelin-36 and ALX40-4C were able to block T-tropic
isolates BH8 and MN gp120, the M-tropic isolate JR-FL,
dual-tropic isolates 89.6 and SF2 gp120, and SIV gp120-
mediated fusion. Of note, Apelin-13 could inhibit fusion
mediated by T-tropic BH8 and MN gp120 and SIV gp120,
but not fusion mediated by dual-tropic 89.6 and SF2 gp120
(Fig. 2).
To further confirm the activities of ALX40-4C in the
inhibition of CXCR4- and APJ-mediated cell membrane
Fig. 1. Dose-dependent inhibition of cell membrane fusion with APJ and gp120 of the HIV-1 T-tropic isolate, IIIB. The 293 cells were infected with a vaccinia
virus encoding T7 polymerase and a vaccinia virus encoding the HIV-1 envelope protein. QT6 cells were transfected with CD4, APJ, and luciferase under
control of the T7 promoter-expressing vectors. Before fusion, the target cells were incubated in the presence or absence of ALX40-4C and Apelins for 30
min. Cell mixtures were maintained at 37°C for 4 to 6 h. Fusion was determined in a luciferase assay. The values are expressed as percentages of the positive
control of luciferase activity and are means  SD of four independent experiments. Background (negative) controls with effector cells lacking Env were
always close to zero in this assay. “Positive control” represents studies with no inhibitor added.
Table 1
Inhibition of cell–cell fusion by apelin and ALX40-4Ca
Peptide IC50 (M)
(IIIB isolate)
IC50 (M)
(89.6 isolate)
Apelin-13 30 N/D
Apelin-36 0.43 0.8
ALX40-4C 3.41 3.1
a IC50 represents the concentration of peptide required to reach 50%
inhibition of cell–cell fusion. Target cells expressed APJ. The IC50 values
shown represent the results obtained from three independent experiments.
N/D, inhibition not detectable at 30 M
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fusion, QT6 cells were transfected with CXCR4, APJ, and
both CXCR4 and APJ, and were then applied to the cell
fusion assay. As indicated as Fig. 3, although SDF-1 was
able to partially block CXCR4-mediated fusion, and Ape-
lin-36 could strongly inhibit APJ-mediated fusion, SDF-1
and Apelin-36 alone were unable to efficiently block
CXCR4/APJ-mediated fusion, while ALX40-4C showed
the potential to quite potently inhibit CXCR4-, APJ-, and
CXCR4/APJ-mediated fusion. Of note, micromolar rather
than nanomolar concentrations of ALX40-4C were neces-
sary to block fusion assays in both APJ- and CXCR4-
expressing indicator cells.
Although unlikely, based on previous data (Doranz et al.,
1997), possible effects of ALX40-4C on CCR5 were eval-
uated. No inhibition of fusion with the dual-tropic isolate
(89.6) and CCR5 was demonstrated with ALX40-4C (Fig.
4). As well, a natural ligand of CCR5, MIP-1, had inhib-
itory activity on fusion in this assay.
Characterization of ALX40-4C binding to APJ
As shown above, ALX40-4C was not only able to block
CXCR4-, APJ-, and CXCR4/APJ-mediated fusion, but
could inhibit T-tropic and dual-tropic HIV-1 isolates gp120-
mediated fusion. Previous reports have demonstrated that
Fig. 3. Inhibition of cell–cell fusion in cells expressing APJ and CXCR4 by
ALX40-4C. As target cells, QT6 cells expressing only APJ (A), only
CXCR4 (B), and both APJ/CXCR4 (C) were used in cell–cell fusion
assays (envelope-IIIB). The target cells were incubated with 20 M Ape-
lin-36, 50 M ALX40-4C, and 300 nM SDF-1. Cell–cell fusion was
determined as described in the legend to Fig. 1. The values are means 
SD of quadruplicate samples, and the results are representative of four
independent experiments. Positive Control: no inhibitors, apelins, or SDF-
1; Negative Control; no envelope.
Fig. 2. Inhibitory activities of cell membrane fusion by ALX40-4C with
different HIV-1 isolates. (A) Inhibition of APJ-mediated fusion with spe-
cific HIV-1 isolates (T-tropic: BH8, dual-tropic: 89.6, M-tropic: JR-FL).
(B) Inhibitory effects of ALX40-4C on other HIV-1 (dual-tropic: SF2;
T-tropic: MN) and SIV isolates, with lower baseline untreated fusion
levels, using APJ as a co-receptor. The target cells were incubated with 30
M Apelin-36, 50 M Apelin-13, and 50 M ALX40-4C. Cell–cell fusion
was determined as described in the legend to Fig. 1. The values are means
 SD of quadruplicate samples, and the results are representative of four
independent experiments. Positive Control: no inhibitor, Negative Control:
no envelope.
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ALX40-4C interacts with the second extracellular loop of
CXCR4 and inhibits infection exclusively by blocking di-
rect virus–CXCR4 interactions (Doranz et al., 1997, 2001).
Here we used competitive binding assays with 125I-Ape-
lin-13 to investigate whether ALX40-4C directly binds to
APJ. The binding results demonstrated that ALX40-4C
could directly bind to APJ with an IC50 of 2.9 M, com-
pared with Apelin-13 with an IC50 of 0.2 nM (Fig. 5). We
demonstrated previously that APJ can be induced to un-
dergo rapid internalization on binding of Apelin-13 and
Apelin-36 (Zhou et al., 2003), but we now show that this
does not occur on binding of ALX40-4C. Treatment with
ALX40-4C, prior to addition of Apelin-13 or Apelin-36,
was able to inhibit receptor internalization (Fig. 6A: see
lowest two panels in figure). Furthermore, we also investi-
gated the intracellular Ca2 mobilization with treatment of
293 cells stably expressing APJ, using Apelin or ALX40-
4C. ALX40-4C was found not to induce intracellular sig-
naling, but was able to eliminate the signaling induced by
Apelin-13 and Apelin-36 (Fig. 6B).
Discussion
ALX40-4C was initially designed as an inhibitor of
HIV-1 Tat-TAR binding (Sumner-Smith et al., 1995). Sub-
sequently, ALX40-4C was identified as an inhibitor able to
interfere with initial virus–target cell interactions that in-
volve HIV-1 gp120 V3 determinants, most efficiently for T
Fig. 5. Competitive binding of 125I-Apelin-13 to APJ with ALX40-4C. The
293 cells, stably transfected with APJ, were incubated with 125I-Apelin-13
(0.2 nM) in the presence of increasing concentrations of cold Apelin-13 or
ALX40-4C, and cell-associated radioactivity was counted via gamma
emissions. The points represent the mean values of three independent
assays, whereas the error bars are the SD.
Fig. 4. ALX40-4C does not inhibit CCR5-mediated fusion. The 293 target cells expressing only CCR5 were used in cell–cell fusion assays with the envelope
of the dual-tropic HIV-1 89.6. The target cells were incubated with either Apelin-36 (20 M), ALX40-4C (50 M), or MIP-1 (300 M). Cell-to-cell fusion
was assayed as in the legend to Fig. 1. Positive Control: no inhibitors. Negative Control: no HIV-1 envelope.
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cell line-adapted strains (O’Brien et al., 1996). Further stud-
ies have demonstrated that ALX40-4C interacts with the
second extracellular loop of CXCR4 and inhibits infection
exclusively by blocking direct virus–CXCR4 interactions
(Doranz et al., 1997, 2001). In the present study, we found
surprisingly that ALX40-4C efficiently inhibits APJ recep-
tor-mediated cell membrane fusion in a dose-dependent
manner. The results with APJ receptor binding and function
assays demonstrated that ALX40-4C, as an antagonist, di-
rectly bound to APJ and prevented ligand-induced intracel-
lular CA2 mobilization and receptor internalization.
Our previous studies have shown that both Apelin-13
and Apelin-36 have the potential to bind to APJ and induce
APJ internalization, but Apelin-36 was found to be more
effective in inhibition of APJ-dependent cell membrane
fusion (Zhou et al., 2003). In the present study, we have
demonstrated that ALX40-4C directly binds to APJ and
inhibits ligand-induced functions and blocks APJ-dependent
cell membrane fusion. Of note, the relatively higher levels
(M) of ALX40-4C required in the present studies, com-
pared with previous studies for ALX40-4C inhibition of
CXCR4 in vitro (nM) (Doranz et al., 1997), is likely due to
our use of a fusion rather than viral infectivity assay system,
as it has been shown previously that cell-to-cell fusion is
less sensitive to entry inhibitors (Rucker et al., 1997). Al-
though ALX40-4C bound to APJ with a higher IC50 (2.9
M) than Apelin-13 (0.2 nM), for inhibition of APJ-depen-
dent cell–cell fusion ALX40-4C was found to be more
potent than Apelin-13. In characterizing the properties of
binding of Apelins to APJ, although Apelin-13 was more
efficiently associated with APJ than Apelin-36, Apelin-36
binding was found to be more difficult to dissociate from
APJ than Apelin-13 (Hosoya et al., 2000). It is possible that
the association rate of Apelin peptides with APJ is the key
factor in ligand-induced functions, such as acidification rate
promotion, cAMP production inhibition, and chemotactic
activity (Hosoya et al., 2000; Tatemoto et al., 1998). None-
theless, the dissociation rate of Apelin peptides bound to
APJ plays the critical role in blocking HIV-1 entry via the
APJ co-receptor.
Previous studies have indicated that the combination of
hydrophobic and charged residues of chemokine ligands
plays an important role in receptor binding (Hammond et
al., 1996; Jerva et al., 1997). Dealwis et al. (1998) have
suggested that the positively charged residues in SDF-1
are critical for forming favorable electrostatic interactions
with the negative charged surfaces of the extracellular loops
of CXCR4. The net charge of extracellular regions of
CXCR4 is 9, while that of APJ is 11. In addition, APJ,
as a co-receptor of HIV-1, is used favorably by T-tropic and
dual-tropic HIV-1 strains (Choe et al., 1998). The V3 loop
of gp120 from T-tropic strains of HIV-1 is found to have a
higher net positive charge than the V3 loop from M-tropic
strains (O’Brien et al., 1996). In addition, Cayabyab et al.,
(2000) demonstrated that the positively charged arginine
residues in the Apelin-15 peptide play an important role in
its specific ability to block HIV-1 entry via the APJ co-
receptor. It is, therefore, likely that APJ has a negatively
charged surface similar to CXCR4 that plays an important
role in ligand binding and HIV-1 gp120 binding. Thus,
ALX40-4C can directly interact with the negatively charged
surface located in extracellular regions of both CXCR4 and
APJ to block ligand binding and HIV-1 fusion.
Our current studies provide evidence for design of small
molecules with the possibility of targeting multiple co-
receptors to block HIV-1 entry of certain human cells. As
APJ is less likely to play a role in HIV-1 entry into primary
peripheral T cells, the interactions of ALX40-4C with APJ
may be most important in the CNS. ALX40-4C may be
useful both for further dissection of HIV-1 pathogenesis in
the CNS and for potential treatment of HIV-1 neuropatho-
genetic processes.
Experimental procedures
Materials
The recombinant human chemokines SDF-1 and
MIP-1 (R&D System Inc.) were lyophilized and dissolved
as 10 M stock solutions in sterile phosphate-buffered sa-
line (PBS) and stored as 20°C in aliquots. They were
diluted to appropriate concentrations immediately before
use. The radio-iodinated human Apelin-13 was purchased
from Amersham Biosciences (Piscataway, NJ, USA). The
specific activity of human 125I-Apelin-13 was 2000 Ci/
mmol. Dulbecco’s modified Eagle’s medium (DMEM), fe-
tal bovine serum, and G418 were purchased from Life
Technologies Inc. Furo-2 and Pluronic F-127 were pur-
chased from Molecular Probes Inc. (Eugene, OR, USA).
The plasmid, pCDNA-APJ, recombinant vaccinia viruses
encoding four envelopes of HIV-1 vBD3 (89.6), and vTF1.1
encoding T7 RNA polymerase were generous gifts from Dr.
Robert W. Doms, University of Pennsylvania. Other lenti-
viral envelopes used in the fusion assays included HIV-1
IIIB, BH8, MN, SF2, JR-FL, and SIV. The vector
pEGFP-N1 was purchased from Clontech Laboratories Inc.
(Palo Alto, CA, USA). The 293 cell line was obtained from
the AIDS Research and Reference Reagent Program (Divi-
sion of AIDS, NIAID, NIH). 293 and QT6 cells were
maintained in Dulbecco’s modified Eagle’s medium plus
10% fetal bovine serum.
Fig. 6. Inhibition of the ligand-induced function of APJ by ALX40-4C. (A) APJ internalization induced by Apelin-13 and Apelin-36 was inhibited by
ALX40-4C. The 293 cells stably expressing APJ-EGFP were treated with the indicated concentrations of ALX40-4C. Apelin-36, and Apelin-13 at 37°C for
40 min. (B) Inhibition of intracellular Ca2 mobilization. Intracellular Ca2 concentrations in 293 cells, stably expressing APJ, were measured in response
to the indicated amounts of Apelin-36, Apelin-13, and ALX40-4C. The data shown are representative of three independent experiments.
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DNA constructions
The full open reading frame of wild-type APJ was am-
plified using a polymerase chain reaction (PCR) and sub-
cloned in-frame into HindIII and BamHI sites of pEGFP-N1
and pcDNA-3 vectors, driven via the CMV immediate-early
promoter. All constructs were sequenced to confirm the
correct nucleotide sequence and orientation. The plasmid
DNA was transfected into 293 cells by the calcium phos-
phate precipitation method. Stable lines were generated by
selection, 24 h posttransfection, with G418 (800 g/ml).
Radioligand binding assay
The stably transfected cells were harvested in PBS (Ca2
and Mg2 free) plus 0.5 nM EDTA and washed twice with
PBS. Ligand binding experiments were performed using a
single concentration (0.2 nM) of 125I-Apelin-13 in the absence
or presence of increasing concentrations of unlabeled Ape-
lin-13 or ALX40-4C in a final volume of 100 l of binding
buffer (50 nM Hepes, pH 7.4, 1 nM CaCl2, 5 nM MgCl2, 0.1%
bovine serum albumin) containing 5  105 cells. Nonspecific
binding was determined by the addition of 1 M unlabeled
Apelin-13. Samples were incubated for 90 min at room tem-
perature. The incubation was terminated by separating the cells
from the binding buffer by centrifugation and washing once
with 500 l of cold binding buffer. Bound ligands were de-
termined by counting gamma emissions. At least three inde-
pendent experiments were performed.
Flow cytometry
Stably APJ transfected 293 cells (2  105) were washed
with fluorescence-activated cell sorting (FACS) buffer
(0.3% bovine serum albumin, 0.05% sodium azide in PBS)
and incubated with an anti-APJ monoclonal antibody (mAb)
MAB856 (10 g/ml) for 30 min at 4°C. After being washed
with FACS buffer, cells were incubated with 10 g fluo-
rescein isothiocyanate (FITC)-conjugated goat anti-mouse
IgG (Sigma) for 30 min at 4°C. After being washed twice
with FACS buffer, cells were fixed in the fixing buffer
(2% paraformaldehyde in PBS), and then analyzed on a
FACScan flow cytometer (Coulter EPICS Elite, Coolten
Corp., Hialeah, FL, USA).
Fluorescence microscopy
The stable APJ-EGFP-expressing 293 cells were seeded
on Nunc two-chamber slides and incubated at 37°C over-
night. After treatment with ALX40-4C and Apelin, cells
were washed in PBS and then fixed in PBS containing 2%
paraformaldehyde for 10 mins. Fluorescence microscopy
was performed on an Olympus System microscope, Model
BX60, with fluorescence attachment BX-FLA.
Intracellular calcium measurements
Following a modified procedure published by others (Don-
nadieu et al., 1994; Heveker et al., 1998), untransduced 293
cells and APJ stably transfected 293 cells were cultured in the
DMEM medium containing 10% FBS. Cells were trypsinized
and washed twice with PBS. For Ca2 mobilization studies, 5
 106/ml cells were loaded with the fluorescent dye fura-2 (3
M) and 0.05% F172, in Hanks’ balanced salt solution (140
mM NaCl, 5 mM KCl, 10 mM Hepes, pH 7.4, 1 mM CaCl2,
1 mM MgCl2, 1 mg/ml glucose, 0.025% BSA), for 30 min at
37°C. The cells were washed three times and resuspended at a
concentration of 30 to 40  106/ml; then 1.5 to 2  106 cells
were tested in the same buffer. Intracellular Ca2 mobilization
was measured using excitation at 340 and 380 nm on a fluo-
rescence spectrometer (Perkin Elmer LS50B, Beaconsfield,
England), on stimulation with Apelin. Intracellular Ca2 con-
centrations were calculated using a fluorescence spectrometer
measurement program.
Gene reporter fusion assay
A gene reporter fusion assay was used to determine the
co-receptor activity of APJ in mediating HIV-1 viral entry
following a modified procedure published by others (Doranz et
al., 1996; Nussbaum et al., 1994; Rucker et al., 1997). Briefly,
the effector 293 cells were infected with recombinant vaccinia
virus with HIV-1 Env proteins and T7 RNA polymerase for
2 h. Infected cells were then trypsinized, washed with PBS,
resuspended in medium, and incubated overnight at 32°C in
the presence of rifampicin (100 g/ml). Target cells were
co-transfected in six-well plates with plasmids encoding CD4,
APJ, and luciferase under control of the T7 promoter, using the
calcium phosphate precipitation method. Four hours after
transfection, cells were lifted, seeded in 24-well plates, and
incubated at 37°C overnight. Before fusion, the target cells
were incubated in the presence or absence of the test Apelin for
30 min. To initiate fusion, 105 effector cells were added to each
well and incubated at 37°C in the presence or absence of the
test Apelin or ALX40-4C. After 5 h of fusion, cells were lysed
in 150 l of reporter lysis buffer (Pharmingen) and assayed for
luciferase activity by using commercially available reagents
(Pharmingen) with a FB12 Luminometer (Zylux Corp.,
Maryville, TN, USA).
Peptide synthesis
The ALX40-4C peptide was prepared by solid-phase
synthesis using Fmoc-strategy on a 430A peptide synthe-
sizer (Applied Biosystems, Foster City, CA, USA) and a
9050 Pepsynthesizer Plus (Perceptive Biosystems, Cam-
bridge, MA, USA). Crude peptides were purified by pre-
parative reverse-phase high-performance liquid chromatog-
raphy using a Dynamax-300Å C18 25-cm  21.4-mm-i.d.
column with flow rate of 9 ml/min and two solvent systems
of 0.1% TFA/H2O and 0.1% TFA/acetonitrile. Fractions
202 N. Zhou et al. / Virology 312 (2003) 196–203
containing the appropriate peptide were pooled together and
lyophilized. The purity of the final product was assessed by
analytical reverse-phase high-performance liquid chroma-
tography, capillary electrophoresis, and matrix-assisted la-
ser desorption/ionization time-of-flight mass spectrometry.
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